RARITAN, N.J., May 13, 2013 —
/PRNewswire/ — Janssen Research & Development, LLC (Janssen)
announced today that the U.S. Food and Drug Administration (FDA) has
granted Priority Review to the New Drug Application (NDA) for simeprevir
(TMC435), an investigational NS3/4A protease inhibitor administered as a
150 mg capsule once daily with pegylated interferon and ribavirin for
the treatment of genotype 1 chronic hepatitis C in adult patients with
compensated liver disease.